Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
URGN UroGen Pharma Ltd
- Stocks
- Healthcare
- NASDAQ: URGN
Price (delayed)
$13.7
Market cap
$631.67M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.98
Enterprise value
$651.51M
Urogen Pharma Ltd. is a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options. UroGen has developed RTGelTM reverse-thermal hydrogel,
Highlights
The gross profit rose by 9% year-on-year
The revenue has grown by 9% YoY
The net income is down by 33% YoY and by 9% QoQ
URGN's debt is up by 27% year-on-year
Key stats
What are the main financial stats of URGN
Market
Valuations
Earnings
Shares outstanding
46.11M
Market cap
$631.67M
Enterprise value
$651.51M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
7.07
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.09
Revenue
$91.87M
Gross profit
$82.39M
Operating income
-$107.96M
Net income
-$138.43M
EBIT
-$121.12M
EBITDA
-$119.79M
Free cash flow
-$107.39M
Per share
Balance sheet
Liquidity
EPS
-$2.98
EPS diluted
-$2.98
Free cash flow per share
-$2.26
Book value per share
-$1.01
Revenue per share
$1.94
TBVPS
$5.22
Total assets
$247.62M
Total liabilities
$294.08M
Debt
$124.95M
Equity
-$46.46M
Working capital
$195.18M
Debt to equity
-2.69
Current ratio
5.65
Quick ratio
5.16
Net debt/EBITDA
-0.17
Margins
Efficiency
Dividend
EBITDA margin
-130.4%
Gross margin
89.7%
Net margin
-150.7%
Operating margin
-117.5%
Return on assets
-49.6%
Return on equity
-97,486.6%
Return on invested capital
-60.1%
Return on capital employed
-58.9%
Return on sales
-131.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
URGN stock price
How has the UroGen Pharma stock price performed over time
Intraday
1.56%
1 week
-4.2%
1 month
223.11%
1 year
-18.36%
YTD
28.64%
QTD
23.87%
Financial performance
How have UroGen Pharma's revenue and profit performed over time
Revenue
$91.87M
Gross profit
$82.39M
Operating income
-$107.96M
Net income
-$138.43M
Gross margin
89.7%
Net margin
-150.7%
The company's operating income has shrunk by 56% YoY and by 12% QoQ
The operating margin is down by 43% year-on-year and by 10% since the previous quarter
The net income is down by 33% YoY and by 9% QoQ
URGN's net margin is down by 22% year-on-year and by 7% since the previous quarter
Price vs fundamentals
How does URGN's price correlate with its fundamentals
Growth
What is UroGen Pharma's growth rate over time
Valuation
What is UroGen Pharma stock price valuation
P/E
N/A
P/B
N/A
P/S
7.07
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.09
The company's EPS rose by 8% YoY
UroGen Pharma's equity has decreased by 16% YoY
The price to sales (P/S) is 92% lower than the 5-year quarterly average of 89.0 but 16% higher than the last 4 quarters average of 6.0
The revenue has grown by 9% YoY
Efficiency
How efficient is UroGen Pharma business performance
The company's return on sales fell by 28% YoY and by 7% QoQ
The ROA has increased by 21% YoY but it has decreased by 4.6% from the previous quarter
URGN's return on invested capital is up by 2.9% since the previous quarter
Dividends
What is URGN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for URGN.
Financial health
How did UroGen Pharma financials performed over time
UroGen Pharma's total assets is 16% lower than its total liabilities
The current ratio is down by 24% year-on-year and by 6% since the previous quarter
The quick ratio has contracted by 24% YoY and by 8% from the previous quarter
The debt to equity has soared by 81% QoQ but it is down by 10% YoY
URGN's debt is up by 27% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.